Header Logo

Connection

Matthew Meriggioli to Humans

Back to Details
This is a "connection" page, showing publications Matthew Meriggioli has written about Humans.
Matthew Meriggioli
Connection Strength
0.622
Humans
  1. Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan; 13(1):118-31.
    View in: PubMed
    Score: 0.028
  2. The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines. JAMA Neurol. 2015 Sep; 72(9):977-9.
    View in: PubMed
    Score: 0.027
  3. Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int. 2015 Mar; 96(3):234-42.
    View in: PubMed
    Score: 0.026
  4. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Aug; 52:64-73.
    View in: PubMed
    Score: 0.024
  5. Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec; 1274:68-76.
    View in: PubMed
    Score: 0.023
  6. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23.
    View in: PubMed
    Score: 0.022
  7. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53.
    View in: PubMed
    Score: 0.022
  8. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012 Jul; 8(5):427-38.
    View in: PubMed
    Score: 0.022
  9. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009 Aug; 40(2):279-86.
    View in: PubMed
    Score: 0.018
  10. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90.
    View in: PubMed
    Score: 0.018
  11. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009; 26:94-108.
    View in: PubMed
    Score: 0.018
  12. Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res. 2008 Sep 15; 68(18):7352-61.
    View in: PubMed
    Score: 0.017
  13. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008; 1132:276-82.
    View in: PubMed
    Score: 0.016
  14. IVIG in myasthenia gravis: getting enough "bang for the buck". Neurology. 2007 Mar 13; 68(11):803-4.
    View in: PubMed
    Score: 0.015
  15. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve. 2006 Nov; 34(5):666-9.
    View in: PubMed
    Score: 0.015
  16. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25; 66(8):1245-7.
    View in: PubMed
    Score: 0.014
  17. Use of immunoassays in neurological diagnosis and research. Neurol Res. 2005 Oct; 27(7):734-40.
    View in: PubMed
    Score: 0.014
  18. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil. 2005 Aug; 84(8):627-38.
    View in: PubMed
    Score: 0.014
  19. Myasthenia gravis: diagnosis. Semin Neurol. 2004 Mar; 24(1):31-9.
    View in: PubMed
    Score: 0.012
  20. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
    View in: PubMed
    Score: 0.012
  21. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
    View in: PubMed
    Score: 0.012
  22. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
    View in: PubMed
    Score: 0.012
  23. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 2003 Sep-Oct; 20(5):382-5.
    View in: PubMed
    Score: 0.012
  24. Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve. 2003 Feb; 27(2):249-51.
    View in: PubMed
    Score: 0.011
  25. Clinical immunopharmacology of autoimmune neuropathies and myopathies. Clin Neuropharmacol. 2002 May-Jun; 25(3):174-81.
    View in: PubMed
    Score: 0.011
  26. Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS. Neurology. 2001 Oct 09; 57(7):1351; author reply 1351-2.
    View in: PubMed
    Score: 0.010
  27. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841.
    View in: PubMed
    Score: 0.010
  28. Myasthenia gravis. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):291-5.
    View in: PubMed
    Score: 0.010
  29. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve. 2000 Aug; 23(8):1287-9.
    View in: PubMed
    Score: 0.010
  30. Electrodiagnostic significance of supramaximally stimulated A-waves. Muscle Nerve. 2000 Jul; 23(7):1117-20.
    View in: PubMed
    Score: 0.010
  31. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve. 2000 Mar; 23(3):433-5.
    View in: PubMed
    Score: 0.009
  32. Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy. Muscle Nerve. 1999 Dec; 22(12):1693-7.
    View in: PubMed
    Score: 0.009
  33. Complex repetitive discharges: cause or effect of neurogenic muscle hypertrophy? Muscle Nerve. 1999 Nov; 22(11):1603-6.
    View in: PubMed
    Score: 0.009
  34. Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy. Muscle Nerve. 1999 Apr; 22(4):532-7.
    View in: PubMed
    Score: 0.009
  35. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2019 01; 6(1):e523.
    View in: PubMed
    Score: 0.009
  36. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
    View in: PubMed
    Score: 0.008
  37. Peripheral neuropathy and connective tissue disease. Watch for this twosome when hunting for a diagnosis. Postgrad Med. 1997 Nov; 102(5):65-8, 71, 75.
    View in: PubMed
    Score: 0.008
  38. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
    View in: PubMed
    Score: 0.007
  39. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8.
    View in: PubMed
    Score: 0.007
  40. Introduction for myasthenia gravis and related disorders. Ann N Y Acad Sci. 2012 Dec; 1274:vii-viii.
    View in: PubMed
    Score: 0.006
  41. Introduction for Myasthenia Gravis and Related Disorders. Ann N Y Acad Sci. 2012 Dec; 1275:vii-viii.
    View in: PubMed
    Score: 0.006
  42. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012 Jun; 45(6):909-17.
    View in: PubMed
    Score: 0.005
  43. Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet. 2011 Aug; 56(8):589-94.
    View in: PubMed
    Score: 0.005
  44. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat. 2011 Feb; 32(2):152-67.
    View in: PubMed
    Score: 0.005
  45. Hashimoto encephalopathy with fulminant myocarditis. Pathol Res Pract. 2010 Oct 15; 206(10):720-2.
    View in: PubMed
    Score: 0.005
  46. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol. 2010 Jan; 84(1):361-71.
    View in: PubMed
    Score: 0.005
  47. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43.
    View in: PubMed
    Score: 0.004
  48. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8.
    View in: PubMed
    Score: 0.003
  49. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
    View in: PubMed
    Score: 0.003
  50. [Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?]. G Ital Nefrol. 2004 Nov-Dec; 21 Suppl 30:S204-7.
    View in: PubMed
    Score: 0.003
  51. Monomelic amyotrophy with late progression. Neuromuscul Disord. 2001 Apr; 11(3):305-8.
    View in: PubMed
    Score: 0.003
  52. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord. 1999 Oct; 9(6-7):417-20.
    View in: PubMed
    Score: 0.002
  53. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Minerva Med. 1998 Nov-Dec; 89(11-12):405-9.
    View in: PubMed
    Score: 0.002
  54. Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. Ren Fail. 1998 Mar; 20(2):357-60.
    View in: PubMed
    Score: 0.002
  55. Coagulation activation in extracorporeal hemodialysis. Int J Artif Organs. 1997 Mar; 20(3):163-5.
    View in: PubMed
    Score: 0.002
  56. [Coagulation in hemodialysis]. Minerva Med. 1996 Nov; 87(11):509-14.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.